nodes	percent_of_prediction	percent_of_DWPC	metapath
Levetiracetam—ABCC2—esophageal cancer	0.457	0.731	CbGaD
Levetiracetam—ABCB1—esophageal cancer	0.168	0.269	CbGaD
Levetiracetam—ABCC2—Carboplatin—esophageal cancer	0.0982	0.349	CbGbCtD
Levetiracetam—ABCC2—Cisplatin—esophageal cancer	0.0839	0.298	CbGbCtD
Levetiracetam—ABCC2—Methotrexate—esophageal cancer	0.0545	0.193	CbGbCtD
Levetiracetam—ABCB1—Cisplatin—esophageal cancer	0.0274	0.0971	CbGbCtD
Levetiracetam—ABCB1—Methotrexate—esophageal cancer	0.0178	0.063	CbGbCtD
Levetiracetam—Psychiatric symptom—Capecitabine—esophageal cancer	0.00381	0.0602	CcSEcCtD
Levetiracetam—SV2A—bronchus—esophageal cancer	0.00271	0.293	CbGeAlD
Levetiracetam—SV2A—lung—esophageal cancer	0.00175	0.189	CbGeAlD
Levetiracetam—Lower respiratory tract infection—Capecitabine—esophageal cancer	0.00128	0.0203	CcSEcCtD
Levetiracetam—CACNA1B—lung—esophageal cancer	0.00121	0.131	CbGeAlD
Levetiracetam—SV2A—lymph node—esophageal cancer	0.0012	0.129	CbGeAlD
Levetiracetam—Panic attack—Capecitabine—esophageal cancer	0.00118	0.0186	CcSEcCtD
Levetiracetam—Depressed mood—Capecitabine—esophageal cancer	0.000982	0.0155	CcSEcCtD
Levetiracetam—ABCC2—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.000974	0.0476	CbGpPWpGaD
Levetiracetam—CACNA1B—Calcium Regulation in the Cardiac Cell—ATP1B2—esophageal cancer	0.000867	0.0424	CbGpPWpGaD
Levetiracetam—ABCC2—Codeine and Morphine Metabolism—ABCB1—esophageal cancer	0.000842	0.0412	CbGpPWpGaD
Levetiracetam—CACNA1B—lymph node—esophageal cancer	0.000827	0.0893	CbGeAlD
Levetiracetam—Balance disorder—Capecitabine—esophageal cancer	0.000803	0.0127	CcSEcCtD
Levetiracetam—CACNA1B—Calcium Regulation in the Cardiac Cell—FKBP1A—esophageal cancer	0.000802	0.0392	CbGpPWpGaD
Levetiracetam—ABCB1—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.000746	0.0365	CbGpPWpGaD
Levetiracetam—Rhinorrhoea—Cisplatin—esophageal cancer	0.000735	0.0116	CcSEcCtD
Levetiracetam—Infection—Carboplatin—esophageal cancer	0.00072	0.0114	CcSEcCtD
Levetiracetam—Raised liver function tests—Methotrexate—esophageal cancer	0.000708	0.0112	CcSEcCtD
Levetiracetam—Pharyngolaryngeal pain—Capecitabine—esophageal cancer	0.00065	0.0103	CcSEcCtD
Levetiracetam—Laryngeal pain—Capecitabine—esophageal cancer	0.000644	0.0102	CcSEcCtD
Levetiracetam—Pain—Carboplatin—esophageal cancer	0.000619	0.00979	CcSEcCtD
Levetiracetam—Throat sore—Capecitabine—esophageal cancer	0.000609	0.00963	CcSEcCtD
Levetiracetam—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.000604	0.00954	CcSEcCtD
Levetiracetam—Hepatocellular injury—Cisplatin—esophageal cancer	0.000596	0.00941	CcSEcCtD
Levetiracetam—Body temperature increased—Carboplatin—esophageal cancer	0.000573	0.00905	CcSEcCtD
Levetiracetam—Fungal infection—Capecitabine—esophageal cancer	0.000568	0.00898	CcSEcCtD
Levetiracetam—Otitis media—Capecitabine—esophageal cancer	0.000564	0.00891	CcSEcCtD
Levetiracetam—Memory impairment—Capecitabine—esophageal cancer	0.000559	0.00884	CcSEcCtD
Levetiracetam—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000559	0.0273	CbGpPWpGaD
Levetiracetam—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000559	0.0273	CbGpPWpGaD
Levetiracetam—Rhinorrhoea—Capecitabine—esophageal cancer	0.000542	0.00856	CcSEcCtD
Levetiracetam—CACNA1B—Calcium Regulation in the Cardiac Cell—GNG7—esophageal cancer	0.000517	0.0253	CbGpPWpGaD
Levetiracetam—CACNA1B—Calcium Regulation in the Cardiac Cell—SFN—esophageal cancer	0.000513	0.0251	CbGpPWpGaD
Levetiracetam—Contusion—Capecitabine—esophageal cancer	0.000503	0.00795	CcSEcCtD
Levetiracetam—Skin discolouration—Capecitabine—esophageal cancer	0.000486	0.00768	CcSEcCtD
Levetiracetam—Oropharyngeal pain—Capecitabine—esophageal cancer	0.000483	0.00763	CcSEcCtD
Levetiracetam—Liver disorder—Methotrexate—esophageal cancer	0.000479	0.00758	CcSEcCtD
Levetiracetam—Nasal congestion—Cisplatin—esophageal cancer	0.000475	0.0075	CcSEcCtD
Levetiracetam—ABCC2—digestive system—esophageal cancer	0.000469	0.0507	CbGeAlD
Levetiracetam—ABCC2—Drug Induction of Bile Acid Pathway—ABCB1—esophageal cancer	0.00046	0.0225	CbGpPWpGaD
Levetiracetam—Amnesia—Cisplatin—esophageal cancer	0.00046	0.00727	CcSEcCtD
Levetiracetam—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.000458	0.0224	CbGpPWpGaD
Levetiracetam—Gait disturbance—Capecitabine—esophageal cancer	0.00045	0.00711	CcSEcCtD
Levetiracetam—Coordination abnormal—Capecitabine—esophageal cancer	0.000447	0.00706	CcSEcCtD
Levetiracetam—Neck pain—Capecitabine—esophageal cancer	0.000444	0.00702	CcSEcCtD
Levetiracetam—Hyponatraemia—Cisplatin—esophageal cancer	0.000434	0.00686	CcSEcCtD
Levetiracetam—Urinary incontinence—Capecitabine—esophageal cancer	0.000424	0.0067	CcSEcCtD
Levetiracetam—Fungal infection—Methotrexate—esophageal cancer	0.000423	0.00669	CcSEcCtD
Levetiracetam—ABCC2—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000418	0.0205	CbGpPWpGaD
Levetiracetam—Face oedema—Cisplatin—esophageal cancer	0.000417	0.0066	CcSEcCtD
Levetiracetam—Gingivitis—Methotrexate—esophageal cancer	0.000416	0.00658	CcSEcCtD
Levetiracetam—Irritability—Cisplatin—esophageal cancer	0.000413	0.00652	CcSEcCtD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.000408	0.02	CbGpPWpGaD
Levetiracetam—CACNA1B—Calcium Regulation in the Cardiac Cell—CALR—esophageal cancer	0.000408	0.02	CbGpPWpGaD
Levetiracetam—ABCB1—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.000408	0.0199	CbGpPWpGaD
Levetiracetam—Dehydration—Cisplatin—esophageal cancer	0.000402	0.00635	CcSEcCtD
Levetiracetam—Mouth ulceration—Capecitabine—esophageal cancer	0.000397	0.00627	CcSEcCtD
Levetiracetam—Ecchymosis—Capecitabine—esophageal cancer	0.000397	0.00627	CcSEcCtD
Levetiracetam—Nasopharyngitis—Cisplatin—esophageal cancer	0.000387	0.00611	CcSEcCtD
Levetiracetam—CACNA1B—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.000383	0.0187	CbGpPWpGaD
Levetiracetam—Mental disability—Capecitabine—esophageal cancer	0.000381	0.00602	CcSEcCtD
Levetiracetam—Ear pain—Capecitabine—esophageal cancer	0.000373	0.0059	CcSEcCtD
Levetiracetam—Pancreatitis—Cisplatin—esophageal cancer	0.000366	0.00579	CcSEcCtD
Levetiracetam—Skin discolouration—Methotrexate—esophageal cancer	0.000362	0.00572	CcSEcCtD
Levetiracetam—Gastroenteritis—Capecitabine—esophageal cancer	0.00036	0.00568	CcSEcCtD
Levetiracetam—Pancytopenia—Cisplatin—esophageal cancer	0.000355	0.00561	CcSEcCtD
Levetiracetam—Hepatic failure—Capecitabine—esophageal cancer	0.000355	0.0056	CcSEcCtD
Levetiracetam—Amnesia—Capecitabine—esophageal cancer	0.000339	0.00536	CcSEcCtD
Levetiracetam—Renal impairment—Capecitabine—esophageal cancer	0.000335	0.00529	CcSEcCtD
Levetiracetam—Dermatitis bullous—Capecitabine—esophageal cancer	0.000333	0.00527	CcSEcCtD
Levetiracetam—Respiratory failure—Methotrexate—esophageal cancer	0.000333	0.00526	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—ALDH3A1—esophageal cancer	0.000332	0.0162	CbGpPWpGaD
Levetiracetam—Lethargy—Capecitabine—esophageal cancer	0.000325	0.00514	CcSEcCtD
Levetiracetam—Stomatitis—Cisplatin—esophageal cancer	0.000325	0.00513	CcSEcCtD
Levetiracetam—Conjunctivitis—Cisplatin—esophageal cancer	0.000324	0.00512	CcSEcCtD
Levetiracetam—Hyponatraemia—Capecitabine—esophageal cancer	0.00032	0.00506	CcSEcCtD
Levetiracetam—SV2A—Disease—SLC52A3—esophageal cancer	0.000319	0.0156	CbGpPWpGaD
Levetiracetam—Diplopia—Capecitabine—esophageal cancer	0.000319	0.00504	CcSEcCtD
Levetiracetam—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000315	0.00498	CcSEcCtD
Levetiracetam—CACNA1B—Neuronal System—GNG7—esophageal cancer	0.000313	0.0153	CbGpPWpGaD
Levetiracetam—Face oedema—Capecitabine—esophageal cancer	0.000308	0.00486	CcSEcCtD
Levetiracetam—SV2A—Disease—KMT2D—esophageal cancer	0.000305	0.0149	CbGpPWpGaD
Levetiracetam—Irritability—Capecitabine—esophageal cancer	0.000304	0.00481	CcSEcCtD
Levetiracetam—Mood swings—Capecitabine—esophageal cancer	0.000302	0.00477	CcSEcCtD
Levetiracetam—Ataxia—Capecitabine—esophageal cancer	0.0003	0.00474	CcSEcCtD
Levetiracetam—Dehydration—Capecitabine—esophageal cancer	0.000296	0.00468	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—BLVRB—esophageal cancer	0.000296	0.0145	CbGpPWpGaD
Levetiracetam—Mouth ulceration—Methotrexate—esophageal cancer	0.000295	0.00467	CcSEcCtD
Levetiracetam—Ecchymosis—Methotrexate—esophageal cancer	0.000295	0.00467	CcSEcCtD
Levetiracetam—Liver function test abnormal—Capecitabine—esophageal cancer	0.000294	0.00465	CcSEcCtD
Levetiracetam—Connective tissue disorder—Cisplatin—esophageal cancer	0.000294	0.00464	CcSEcCtD
Levetiracetam—CACNA1B—Neuronal System—ALDH2—esophageal cancer	0.000293	0.0143	CbGpPWpGaD
Levetiracetam—Abdominal pain upper—Capecitabine—esophageal cancer	0.000291	0.0046	CcSEcCtD
Levetiracetam—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000287	0.00453	CcSEcCtD
Levetiracetam—Nasopharyngitis—Capecitabine—esophageal cancer	0.000285	0.0045	CcSEcCtD
Levetiracetam—Muscular weakness—Capecitabine—esophageal cancer	0.000281	0.00444	CcSEcCtD
Levetiracetam—Eye disorder—Cisplatin—esophageal cancer	0.000279	0.00442	CcSEcCtD
Levetiracetam—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000278	0.0136	CbGpPWpGaD
Levetiracetam—Asthma—Capecitabine—esophageal cancer	0.000275	0.00435	CcSEcCtD
Levetiracetam—Influenza—Capecitabine—esophageal cancer	0.000275	0.00435	CcSEcCtD
Levetiracetam—Immune system disorder—Cisplatin—esophageal cancer	0.00027	0.00427	CcSEcCtD
Levetiracetam—Mediastinal disorder—Cisplatin—esophageal cancer	0.00027	0.00426	CcSEcCtD
Levetiracetam—ABCC2—lymph node—esophageal cancer	0.000268	0.0289	CbGeAlD
Levetiracetam—Bronchitis—Capecitabine—esophageal cancer	0.000265	0.00419	CcSEcCtD
Levetiracetam—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000264	0.0129	CbGpPWpGaD
Levetiracetam—Alopecia—Cisplatin—esophageal cancer	0.000264	0.00418	CcSEcCtD
Levetiracetam—Hepatic failure—Methotrexate—esophageal cancer	0.000264	0.00417	CcSEcCtD
Levetiracetam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.000263	0.0129	CbGpPWpGaD
Levetiracetam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.000263	0.0129	CbGpPWpGaD
Levetiracetam—Pancytopenia—Capecitabine—esophageal cancer	0.000262	0.00413	CcSEcCtD
Levetiracetam—Malnutrition—Cisplatin—esophageal cancer	0.00026	0.00411	CcSEcCtD
Levetiracetam—Neutropenia—Capecitabine—esophageal cancer	0.000258	0.00407	CcSEcCtD
Levetiracetam—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000256	0.00405	CcSEcCtD
Levetiracetam—ABCC2—ABC-family proteins mediated transport—ABCB1—esophageal cancer	0.000253	0.0124	CbGpPWpGaD
Levetiracetam—ABCC2—NRF2 pathway—PRDX1—esophageal cancer	0.000251	0.0123	CbGpPWpGaD
Levetiracetam—Weight increased—Capecitabine—esophageal cancer	0.000251	0.00396	CcSEcCtD
Levetiracetam—Weight decreased—Capecitabine—esophageal cancer	0.000249	0.00394	CcSEcCtD
Levetiracetam—ABCB1—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.000246	0.012	CbGpPWpGaD
Levetiracetam—Infestation—Capecitabine—esophageal cancer	0.000246	0.00388	CcSEcCtD
Levetiracetam—Infestation NOS—Capecitabine—esophageal cancer	0.000246	0.00388	CcSEcCtD
Levetiracetam—Vision blurred—Cisplatin—esophageal cancer	0.000245	0.00388	CcSEcCtD
Levetiracetam—Depression—Capecitabine—esophageal cancer	0.000245	0.00387	CcSEcCtD
Levetiracetam—Tremor—Cisplatin—esophageal cancer	0.000244	0.00385	CcSEcCtD
Levetiracetam—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000243	0.00385	CcSEcCtD
Levetiracetam—Lethargy—Methotrexate—esophageal cancer	0.000242	0.00383	CcSEcCtD
Levetiracetam—Stomatitis—Capecitabine—esophageal cancer	0.000239	0.00378	CcSEcCtD
Levetiracetam—Urinary tract infection—Capecitabine—esophageal cancer	0.000239	0.00377	CcSEcCtD
Levetiracetam—Conjunctivitis—Capecitabine—esophageal cancer	0.000239	0.00377	CcSEcCtD
Levetiracetam—SV2A—Disease—FKBP1A—esophageal cancer	0.000236	0.0116	CbGpPWpGaD
Levetiracetam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.000234	0.0115	CbGpPWpGaD
Levetiracetam—Leukopenia—Cisplatin—esophageal cancer	0.000233	0.00368	CcSEcCtD
Levetiracetam—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000232	0.00367	CcSEcCtD
Levetiracetam—Epistaxis—Capecitabine—esophageal cancer	0.000232	0.00366	CcSEcCtD
Levetiracetam—SV2A—Disease—WIF1—esophageal cancer	0.000231	0.0113	CbGpPWpGaD
Levetiracetam—SV2A—Disease—DOCK2—esophageal cancer	0.000231	0.0113	CbGpPWpGaD
Levetiracetam—Agranulocytosis—Capecitabine—esophageal cancer	0.000229	0.00362	CcSEcCtD
Levetiracetam—Irritability—Methotrexate—esophageal cancer	0.000226	0.00358	CcSEcCtD
Levetiracetam—Convulsion—Cisplatin—esophageal cancer	0.000226	0.00356	CcSEcCtD
Levetiracetam—Mood swings—Methotrexate—esophageal cancer	0.000225	0.00355	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—SLC39A6—esophageal cancer	0.000224	0.011	CbGpPWpGaD
Levetiracetam—ABCB1—ABC-family proteins mediated transport—ABCC2—esophageal cancer	0.000224	0.0109	CbGpPWpGaD
Levetiracetam—Ataxia—Methotrexate—esophageal cancer	0.000223	0.00353	CcSEcCtD
Levetiracetam—Myalgia—Cisplatin—esophageal cancer	0.000222	0.0035	CcSEcCtD
Levetiracetam—ABCB1—epithelium—esophageal cancer	0.000222	0.0239	CbGeAlD
Levetiracetam—Rhinitis—Capecitabine—esophageal cancer	0.000221	0.00349	CcSEcCtD
Levetiracetam—Anxiety—Cisplatin—esophageal cancer	0.000221	0.00349	CcSEcCtD
Levetiracetam—Hepatitis—Capecitabine—esophageal cancer	0.00022	0.00348	CcSEcCtD
Levetiracetam—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00022	0.00348	CcSEcCtD
Levetiracetam—Liver function test abnormal—Methotrexate—esophageal cancer	0.000219	0.00346	CcSEcCtD
Levetiracetam—Pharyngitis—Capecitabine—esophageal cancer	0.000219	0.00346	CcSEcCtD
Levetiracetam—Connective tissue disorder—Capecitabine—esophageal cancer	0.000217	0.00342	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—ADH7—esophageal cancer	0.000214	0.0105	CbGpPWpGaD
Levetiracetam—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000214	0.00338	CcSEcCtD
Levetiracetam—SV2A—Disease—CSNK1A1—esophageal cancer	0.000213	0.0104	CbGpPWpGaD
Levetiracetam—Infection—Cisplatin—esophageal cancer	0.000211	0.00334	CcSEcCtD
Levetiracetam—Erythema multiforme—Capecitabine—esophageal cancer	0.000208	0.00329	CcSEcCtD
Levetiracetam—Nervous system disorder—Cisplatin—esophageal cancer	0.000208	0.00329	CcSEcCtD
Levetiracetam—Thrombocytopenia—Cisplatin—esophageal cancer	0.000208	0.00329	CcSEcCtD
Levetiracetam—Skin disorder—Cisplatin—esophageal cancer	0.000206	0.00326	CcSEcCtD
Levetiracetam—Eye disorder—Capecitabine—esophageal cancer	0.000206	0.00326	CcSEcCtD
Levetiracetam—Asthma—Methotrexate—esophageal cancer	0.000205	0.00324	CcSEcCtD
Levetiracetam—Eosinophilia—Methotrexate—esophageal cancer	0.000203	0.00321	CcSEcCtD
Levetiracetam—Anorexia—Cisplatin—esophageal cancer	0.000203	0.0032	CcSEcCtD
Levetiracetam—Pancreatitis—Methotrexate—esophageal cancer	0.000201	0.00318	CcSEcCtD
Levetiracetam—Immune system disorder—Capecitabine—esophageal cancer	0.000199	0.00315	CcSEcCtD
Levetiracetam—Mediastinal disorder—Capecitabine—esophageal cancer	0.000199	0.00314	CcSEcCtD
Levetiracetam—ABCB1—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.000197	0.00962	CbGpPWpGaD
Levetiracetam—ABCB1—trachea—esophageal cancer	0.000196	0.0212	CbGeAlD
Levetiracetam—Alopecia—Capecitabine—esophageal cancer	0.000195	0.00308	CcSEcCtD
Levetiracetam—Pancytopenia—Methotrexate—esophageal cancer	0.000195	0.00308	CcSEcCtD
Levetiracetam—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000194	0.00306	CcSEcCtD
Levetiracetam—Mental disorder—Capecitabine—esophageal cancer	0.000193	0.00305	CcSEcCtD
Levetiracetam—Malnutrition—Capecitabine—esophageal cancer	0.000192	0.00303	CcSEcCtD
Levetiracetam—Neutropenia—Methotrexate—esophageal cancer	0.000192	0.00303	CcSEcCtD
Levetiracetam—Paraesthesia—Cisplatin—esophageal cancer	0.000191	0.00302	CcSEcCtD
Levetiracetam—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000191	0.00301	CcSEcCtD
Levetiracetam—Back pain—Capecitabine—esophageal cancer	0.000186	0.00293	CcSEcCtD
Levetiracetam—Decreased appetite—Cisplatin—esophageal cancer	0.000185	0.00292	CcSEcCtD
Levetiracetam—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000183	0.0029	CcSEcCtD
Levetiracetam—Infestation—Methotrexate—esophageal cancer	0.000183	0.00289	CcSEcCtD
Levetiracetam—Drowsiness—Methotrexate—esophageal cancer	0.000183	0.00289	CcSEcCtD
Levetiracetam—Infestation NOS—Methotrexate—esophageal cancer	0.000183	0.00289	CcSEcCtD
Levetiracetam—Depression—Methotrexate—esophageal cancer	0.000182	0.00288	CcSEcCtD
Levetiracetam—Pain—Cisplatin—esophageal cancer	0.000182	0.00287	CcSEcCtD
Levetiracetam—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000181	0.00286	CcSEcCtD
Levetiracetam—Vision blurred—Capecitabine—esophageal cancer	0.000181	0.00286	CcSEcCtD
Levetiracetam—Tremor—Capecitabine—esophageal cancer	0.00018	0.00284	CcSEcCtD
Levetiracetam—SV2A—Disease—ELMO1—esophageal cancer	0.000179	0.00876	CbGpPWpGaD
Levetiracetam—Stomatitis—Methotrexate—esophageal cancer	0.000178	0.00282	CcSEcCtD
Levetiracetam—Conjunctivitis—Methotrexate—esophageal cancer	0.000178	0.00281	CcSEcCtD
Levetiracetam—Feeling abnormal—Cisplatin—esophageal cancer	0.000175	0.00277	CcSEcCtD
Levetiracetam—SV2A—Disease—TPI1—esophageal cancer	0.000175	0.00856	CbGpPWpGaD
Levetiracetam—SV2A—Disease—GSTO1—esophageal cancer	0.000175	0.00856	CbGpPWpGaD
Levetiracetam—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000173	0.00273	CcSEcCtD
Levetiracetam—Epistaxis—Methotrexate—esophageal cancer	0.000172	0.00273	CcSEcCtD
Levetiracetam—Vertigo—Capecitabine—esophageal cancer	0.000172	0.00272	CcSEcCtD
Levetiracetam—Leukopenia—Capecitabine—esophageal cancer	0.000172	0.00271	CcSEcCtD
Levetiracetam—Agranulocytosis—Methotrexate—esophageal cancer	0.000171	0.0027	CcSEcCtD
Levetiracetam—ABCB1—digestive system—esophageal cancer	0.000169	0.0182	CbGeAlD
Levetiracetam—Body temperature increased—Cisplatin—esophageal cancer	0.000168	0.00265	CcSEcCtD
Levetiracetam—SV2A—Disease—ALDOB—esophageal cancer	0.000168	0.00821	CbGpPWpGaD
Levetiracetam—Cough—Capecitabine—esophageal cancer	0.000167	0.00265	CcSEcCtD
Levetiracetam—Hepatitis—Methotrexate—esophageal cancer	0.000164	0.00259	CcSEcCtD
Levetiracetam—Myalgia—Capecitabine—esophageal cancer	0.000163	0.00258	CcSEcCtD
Levetiracetam—Chest pain—Capecitabine—esophageal cancer	0.000163	0.00258	CcSEcCtD
Levetiracetam—Arthralgia—Capecitabine—esophageal cancer	0.000163	0.00258	CcSEcCtD
Levetiracetam—Pharyngitis—Methotrexate—esophageal cancer	0.000163	0.00257	CcSEcCtD
Levetiracetam—Anxiety—Capecitabine—esophageal cancer	0.000163	0.00257	CcSEcCtD
Levetiracetam—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000162	0.00256	CcSEcCtD
Levetiracetam—SV2A—Disease—HIST1H2BM—esophageal cancer	0.000162	0.0079	CbGpPWpGaD
Levetiracetam—SV2A—Disease—GAPDH—esophageal cancer	0.000162	0.0079	CbGpPWpGaD
Levetiracetam—Confusional state—Capecitabine—esophageal cancer	0.000158	0.0025	CcSEcCtD
Levetiracetam—Hypersensitivity—Cisplatin—esophageal cancer	0.000157	0.00247	CcSEcCtD
Levetiracetam—Infection—Capecitabine—esophageal cancer	0.000156	0.00246	CcSEcCtD
Levetiracetam—Erythema multiforme—Methotrexate—esophageal cancer	0.000155	0.00245	CcSEcCtD
Levetiracetam—Nervous system disorder—Capecitabine—esophageal cancer	0.000154	0.00243	CcSEcCtD
Levetiracetam—Eye disorder—Methotrexate—esophageal cancer	0.000153	0.00242	CcSEcCtD
Levetiracetam—Thrombocytopenia—Capecitabine—esophageal cancer	0.000153	0.00242	CcSEcCtD
Levetiracetam—Asthenia—Cisplatin—esophageal cancer	0.000152	0.00241	CcSEcCtD
Levetiracetam—Skin disorder—Capecitabine—esophageal cancer	0.000152	0.0024	CcSEcCtD
Levetiracetam—Anorexia—Capecitabine—esophageal cancer	0.000149	0.00236	CcSEcCtD
Levetiracetam—Immune system disorder—Methotrexate—esophageal cancer	0.000148	0.00234	CcSEcCtD
Levetiracetam—Mediastinal disorder—Methotrexate—esophageal cancer	0.000148	0.00234	CcSEcCtD
Levetiracetam—Diarrhoea—Cisplatin—esophageal cancer	0.000145	0.0023	CcSEcCtD
Levetiracetam—Alopecia—Methotrexate—esophageal cancer	0.000145	0.00229	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—NFE2L2—esophageal cancer	0.000144	0.00706	CbGpPWpGaD
Levetiracetam—Mental disorder—Methotrexate—esophageal cancer	0.000144	0.00227	CcSEcCtD
Levetiracetam—Malnutrition—Methotrexate—esophageal cancer	0.000143	0.00226	CcSEcCtD
Levetiracetam—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000143	0.00226	CcSEcCtD
Levetiracetam—SV2A—Disease—XIAP—esophageal cancer	0.000143	0.00698	CbGpPWpGaD
Levetiracetam—Insomnia—Capecitabine—esophageal cancer	0.000142	0.00224	CcSEcCtD
Levetiracetam—ABCB1—lung—esophageal cancer	0.000141	0.0152	CbGeAlD
Levetiracetam—Paraesthesia—Capecitabine—esophageal cancer	0.000141	0.00222	CcSEcCtD
Levetiracetam—Back pain—Methotrexate—esophageal cancer	0.000138	0.00218	CcSEcCtD
Levetiracetam—Dyspepsia—Capecitabine—esophageal cancer	0.000138	0.00218	CcSEcCtD
Levetiracetam—Decreased appetite—Capecitabine—esophageal cancer	0.000136	0.00215	CcSEcCtD
Levetiracetam—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000135	0.00214	CcSEcCtD
Levetiracetam—Vomiting—Cisplatin—esophageal cancer	0.000135	0.00213	CcSEcCtD
Levetiracetam—Fatigue—Capecitabine—esophageal cancer	0.000135	0.00213	CcSEcCtD
Levetiracetam—Vision blurred—Methotrexate—esophageal cancer	0.000135	0.00213	CcSEcCtD
Levetiracetam—Rash—Cisplatin—esophageal cancer	0.000134	0.00212	CcSEcCtD
Levetiracetam—Pain—Capecitabine—esophageal cancer	0.000134	0.00212	CcSEcCtD
Levetiracetam—Constipation—Capecitabine—esophageal cancer	0.000134	0.00212	CcSEcCtD
Levetiracetam—Dermatitis—Cisplatin—esophageal cancer	0.000134	0.00212	CcSEcCtD
Levetiracetam—SV2A—Disease—B2M—esophageal cancer	0.000133	0.00649	CbGpPWpGaD
Levetiracetam—Feeling abnormal—Capecitabine—esophageal cancer	0.000129	0.00204	CcSEcCtD
Levetiracetam—Vertigo—Methotrexate—esophageal cancer	0.000128	0.00203	CcSEcCtD
Levetiracetam—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000128	0.00202	CcSEcCtD
Levetiracetam—Leukopenia—Methotrexate—esophageal cancer	0.000128	0.00202	CcSEcCtD
Levetiracetam—SV2A—Disease—ENO1—esophageal cancer	0.000127	0.00622	CbGpPWpGaD
Levetiracetam—Nausea—Cisplatin—esophageal cancer	0.000126	0.00199	CcSEcCtD
Levetiracetam—SV2A—Disease—PSME2—esophageal cancer	0.000125	0.00613	CbGpPWpGaD
Levetiracetam—SV2A—Disease—PSME1—esophageal cancer	0.000125	0.00613	CbGpPWpGaD
Levetiracetam—Cough—Methotrexate—esophageal cancer	0.000125	0.00197	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—CYP2A6—esophageal cancer	0.000124	0.00607	CbGpPWpGaD
Levetiracetam—Body temperature increased—Capecitabine—esophageal cancer	0.000124	0.00196	CcSEcCtD
Levetiracetam—Abdominal pain—Capecitabine—esophageal cancer	0.000124	0.00196	CcSEcCtD
Levetiracetam—Convulsion—Methotrexate—esophageal cancer	0.000124	0.00196	CcSEcCtD
Levetiracetam—Chest pain—Methotrexate—esophageal cancer	0.000122	0.00192	CcSEcCtD
Levetiracetam—Arthralgia—Methotrexate—esophageal cancer	0.000122	0.00192	CcSEcCtD
Levetiracetam—Myalgia—Methotrexate—esophageal cancer	0.000122	0.00192	CcSEcCtD
Levetiracetam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000121	0.00191	CcSEcCtD
Levetiracetam—SV2A—Disease—CALR—esophageal cancer	0.00012	0.00588	CbGpPWpGaD
Levetiracetam—Confusional state—Methotrexate—esophageal cancer	0.000118	0.00186	CcSEcCtD
Levetiracetam—SV2A—Disease—FBXW7—esophageal cancer	0.000116	0.00569	CbGpPWpGaD
Levetiracetam—Infection—Methotrexate—esophageal cancer	0.000116	0.00183	CcSEcCtD
Levetiracetam—Hypersensitivity—Capecitabine—esophageal cancer	0.000115	0.00182	CcSEcCtD
Levetiracetam—Nervous system disorder—Methotrexate—esophageal cancer	0.000114	0.00181	CcSEcCtD
Levetiracetam—Thrombocytopenia—Methotrexate—esophageal cancer	0.000114	0.0018	CcSEcCtD
Levetiracetam—Skin disorder—Methotrexate—esophageal cancer	0.000113	0.00179	CcSEcCtD
Levetiracetam—Asthenia—Capecitabine—esophageal cancer	0.000112	0.00178	CcSEcCtD
Levetiracetam—Anorexia—Methotrexate—esophageal cancer	0.000111	0.00176	CcSEcCtD
Levetiracetam—Pruritus—Capecitabine—esophageal cancer	0.000111	0.00175	CcSEcCtD
Levetiracetam—Diarrhoea—Capecitabine—esophageal cancer	0.000107	0.00169	CcSEcCtD
Levetiracetam—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000106	0.00168	CcSEcCtD
Levetiracetam—Insomnia—Methotrexate—esophageal cancer	0.000105	0.00167	CcSEcCtD
Levetiracetam—Paraesthesia—Methotrexate—esophageal cancer	0.000105	0.00165	CcSEcCtD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—ENO1—esophageal cancer	0.000104	0.00511	CbGpPWpGaD
Levetiracetam—Somnolence—Methotrexate—esophageal cancer	0.000104	0.00164	CcSEcCtD
Levetiracetam—Dizziness—Capecitabine—esophageal cancer	0.000104	0.00164	CcSEcCtD
Levetiracetam—Dyspepsia—Methotrexate—esophageal cancer	0.000103	0.00162	CcSEcCtD
Levetiracetam—Decreased appetite—Methotrexate—esophageal cancer	0.000101	0.0016	CcSEcCtD
Levetiracetam—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000101	0.00159	CcSEcCtD
Levetiracetam—Fatigue—Methotrexate—esophageal cancer	0.000101	0.00159	CcSEcCtD
Levetiracetam—Pain—Methotrexate—esophageal cancer	9.97e-05	0.00158	CcSEcCtD
Levetiracetam—Vomiting—Capecitabine—esophageal cancer	9.96e-05	0.00157	CcSEcCtD
Levetiracetam—Rash—Capecitabine—esophageal cancer	9.87e-05	0.00156	CcSEcCtD
Levetiracetam—Dermatitis—Capecitabine—esophageal cancer	9.87e-05	0.00156	CcSEcCtD
Levetiracetam—Headache—Capecitabine—esophageal cancer	9.81e-05	0.00155	CcSEcCtD
Levetiracetam—ABCB1—lymph node—esophageal cancer	9.63e-05	0.0104	CbGeAlD
Levetiracetam—Feeling abnormal—Methotrexate—esophageal cancer	9.61e-05	0.00152	CcSEcCtD
Levetiracetam—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—esophageal cancer	9.58e-05	0.00469	CbGpPWpGaD
Levetiracetam—Gastrointestinal pain—Methotrexate—esophageal cancer	9.53e-05	0.00151	CcSEcCtD
Levetiracetam—SV2A—Disease—TGFBR2—esophageal cancer	9.41e-05	0.0046	CbGpPWpGaD
Levetiracetam—Nausea—Capecitabine—esophageal cancer	9.3e-05	0.00147	CcSEcCtD
Levetiracetam—Body temperature increased—Methotrexate—esophageal cancer	9.22e-05	0.00146	CcSEcCtD
Levetiracetam—Abdominal pain—Methotrexate—esophageal cancer	9.22e-05	0.00146	CcSEcCtD
Levetiracetam—SV2A—Disease—SMAD4—esophageal cancer	8.9e-05	0.00435	CbGpPWpGaD
Levetiracetam—ABCC2—NRF2 pathway—TGFBR2—esophageal cancer	8.71e-05	0.00426	CbGpPWpGaD
Levetiracetam—Hypersensitivity—Methotrexate—esophageal cancer	8.59e-05	0.00136	CcSEcCtD
Levetiracetam—ABCC2—NRF2 pathway—HMOX1—esophageal cancer	8.59e-05	0.0042	CbGpPWpGaD
Levetiracetam—Asthenia—Methotrexate—esophageal cancer	8.36e-05	0.00132	CcSEcCtD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	8.3e-05	0.00406	CbGpPWpGaD
Levetiracetam—Pruritus—Methotrexate—esophageal cancer	8.25e-05	0.0013	CcSEcCtD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	8.05e-05	0.00394	CbGpPWpGaD
Levetiracetam—Diarrhoea—Methotrexate—esophageal cancer	7.98e-05	0.00126	CcSEcCtD
Levetiracetam—Dizziness—Methotrexate—esophageal cancer	7.71e-05	0.00122	CcSEcCtD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—HMOX1—esophageal cancer	7.62e-05	0.00373	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	7.57e-05	0.0037	CbGpPWpGaD
Levetiracetam—Vomiting—Methotrexate—esophageal cancer	7.41e-05	0.00117	CcSEcCtD
Levetiracetam—Rash—Methotrexate—esophageal cancer	7.35e-05	0.00116	CcSEcCtD
Levetiracetam—Dermatitis—Methotrexate—esophageal cancer	7.34e-05	0.00116	CcSEcCtD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—SMAD4—esophageal cancer	7.31e-05	0.00358	CbGpPWpGaD
Levetiracetam—Headache—Methotrexate—esophageal cancer	7.3e-05	0.00115	CcSEcCtD
Levetiracetam—SV2A—Disease—HIF1A—esophageal cancer	7.29e-05	0.00356	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	7.18e-05	0.00351	CbGpPWpGaD
Levetiracetam—Nausea—Methotrexate—esophageal cancer	6.93e-05	0.00109	CcSEcCtD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—AQP3—esophageal cancer	6.85e-05	0.00335	CbGpPWpGaD
Levetiracetam—SV2A—Disease—NOS2—esophageal cancer	6.63e-05	0.00324	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	6.56e-05	0.00321	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	6.56e-05	0.00321	CbGpPWpGaD
Levetiracetam—SV2A—Disease—NOTCH1—esophageal cancer	6.56e-05	0.00321	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	6.44e-05	0.00315	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	5.99e-05	0.00293	CbGpPWpGaD
Levetiracetam—SV2A—Disease—CREBBP—esophageal cancer	5.95e-05	0.00291	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	5.44e-05	0.00266	CbGpPWpGaD
Levetiracetam—SV2A—Disease—NOS3—esophageal cancer	5.33e-05	0.00261	CbGpPWpGaD
Levetiracetam—SV2A—Disease—ERBB2—esophageal cancer	4.98e-05	0.00244	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	4.89e-05	0.00239	CbGpPWpGaD
Levetiracetam—SV2A—Disease—PTGS2—esophageal cancer	4.87e-05	0.00238	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—GNG7—esophageal cancer	4.51e-05	0.00221	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	4.38e-05	0.00214	CbGpPWpGaD
Levetiracetam—SV2A—Disease—CDKN1A—esophageal cancer	4.26e-05	0.00208	CbGpPWpGaD
Levetiracetam—ABCB1—Allograft Rejection—CASP8—esophageal cancer	4.25e-05	0.00208	CbGpPWpGaD
Levetiracetam—SV2A—Disease—EP300—esophageal cancer	4.05e-05	0.00198	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	4e-05	0.00196	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	3.81e-05	0.00186	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	3.79e-05	0.00185	CbGpPWpGaD
Levetiracetam—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	3.68e-05	0.0018	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	3.56e-05	0.00174	CbGpPWpGaD
Levetiracetam—SV2A—Disease—MYC—esophageal cancer	3.53e-05	0.00173	CbGpPWpGaD
Levetiracetam—SV2A—Disease—EGFR—esophageal cancer	3.45e-05	0.00169	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	3.37e-05	0.00165	CbGpPWpGaD
Levetiracetam—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	3.33e-05	0.00163	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	3.23e-05	0.00158	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	3.22e-05	0.00157	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	3.13e-05	0.00153	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	3.09e-05	0.00151	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	3.09e-05	0.00151	CbGpPWpGaD
Levetiracetam—SV2A—Disease—PIK3CA—esophageal cancer	3e-05	0.00147	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	2.96e-05	0.00145	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	2.75e-05	0.00134	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	2.64e-05	0.00129	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	2.34e-05	0.00114	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	2.12e-05	0.00104	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	2.1e-05	0.00103	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	2.09e-05	0.00102	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—BLVRB—esophageal cancer	2.09e-05	0.00102	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—SLC52A3—esophageal cancer	2.09e-05	0.00102	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	1.8e-05	0.000881	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CA1—esophageal cancer	1.77e-05	0.000867	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—SLC10A2—esophageal cancer	1.77e-05	0.000867	CbGpPWpGaD
Levetiracetam—ABCC2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.76e-05	0.000863	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	1.75e-05	0.000856	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	1.71e-05	0.000837	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CA2—esophageal cancer	1.62e-05	0.000793	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.55e-05	0.000756	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—ADH7—esophageal cancer	1.51e-05	0.000737	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PLCE1—esophageal cancer	1.51e-05	0.000737	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.5e-05	0.000731	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	1.42e-05	0.000696	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—ADH1B—esophageal cancer	1.32e-05	0.000646	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.29e-05	0.000632	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—TYMP—esophageal cancer	1.26e-05	0.000618	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	1.24e-05	0.000606	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CYP26A1—esophageal cancer	1.23e-05	0.000601	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	1.21e-05	0.000593	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—ALOX15—esophageal cancer	1.2e-05	0.000586	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GSTO1—esophageal cancer	1.14e-05	0.000559	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—TPI1—esophageal cancer	1.14e-05	0.000559	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—ALDOB—esophageal cancer	1.1e-05	0.000536	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GAPDH—esophageal cancer	1.05e-05	0.000516	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.05e-05	0.000515	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CRABP1—esophageal cancer	1.05e-05	0.000511	CbGpPWpGaD
Levetiracetam—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.02e-05	0.000498	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GNG7—esophageal cancer	9.94e-06	0.000486	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—ALDH2—esophageal cancer	9.32e-06	0.000455	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—GSTT1—esophageal cancer	8.86e-06	0.000433	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CYP2A6—esophageal cancer	8.76e-06	0.000428	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PTGS1—esophageal cancer	8.3e-06	0.000406	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—ENO1—esophageal cancer	8.3e-06	0.000406	CbGpPWpGaD
Levetiracetam—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	8.3e-06	0.000406	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PSME2—esophageal cancer	8.18e-06	0.0004	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PSME1—esophageal cancer	8.18e-06	0.0004	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CYP1B1—esophageal cancer	7.06e-06	0.000345	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CYP19A1—esophageal cancer	6.64e-06	0.000325	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—HMOX1—esophageal cancer	6.06e-06	0.000296	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—CREBBP—esophageal cancer	3.89e-06	0.00019	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—NOS3—esophageal cancer	3.48e-06	0.00017	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PTGS2—esophageal cancer	3.18e-06	0.000156	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—EP300—esophageal cancer	2.65e-06	0.000129	CbGpPWpGaD
Levetiracetam—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.96e-06	9.57e-05	CbGpPWpGaD
